Fermenta Biotech Q1 FY26 earnings call: Revenue & Margins
Q1 FY26 investor presentation: what the company reported on revenue, margins and capex.
- Revenue
- ₹136Cr
- +74.4% YoY
- −2.6% QoQ
- Net profit
- ₹22Cr
- Turned profitable YoY
- −35.2% QoQ
- Margin
- 20.73%
- +19.7 pp YoY
- −5.7 pp QoQ
Top 10 Pharmaceuticals & Biotechnology companies on management guidance
See the sector's top 10 — free with your mobile number.
Based on Fermenta Biotech Ltd's Q1 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Q1FY26 Revenue from operations: INR 136 crore, up 79% YoY (Page 8) - Total Income Q1FY26: INR 145 crore, up 79% YoY (Page 8) - Nutrition business revenue Q1FY26: INR 114.6 crore, up 85% YoY (Page 7) - Human Nutrition volume growth: 83% YoY, 8% QoQ (Page 5) - Animal Nutrition volume growth: 45% YoY, down 17% QoQ (Page 5) - German subsidiary Q1FY26 revenue: INR 15.7 crore, up 588% YoY (Page 5) - EBITDA Q1FY26 INR 37 crore, up 922% YoY (Page 6) - Profit after tax Q1FY26 INR 21.6 crore vs loss last year (Page 6) - EBITDA for Q1FY26: INR 37 crore (up 922% YoY, down 9% QoQ) — Slide 6 - Operating EBITDA (without Real Estate): INR 35.3 crore (up 625% YoY, up 9% QoQ) — Slide 5 - Profit After Tax (PAT) for Q1FY26: INR 21.6 crore (vs INR 5.9 crore loss YoY, down 35% QoQ) — Slide 6
From Fermenta Biotech Ltd's Q1 FY26 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Q1FY26 Revenue from operations: INR 136 crore, up 79% YoY (Page 8)
- Total Income Q1FY26: INR 145 crore, up 79% YoY (Page 8)
- Nutrition business revenue Q1FY26: INR 114.6 crore, up 85% YoY (Page 7)
- Human Nutrition volume growth: 83% YoY, 8% QoQ (Page 5)
- Animal Nutrition volume growth: 45% YoY, down 17% QoQ (Page 5)
- German subsidiary Q1FY26 revenue: INR 15.7 crore, up 588% YoY (Page 5)
- EBITDA Q1FY26 INR 37 crore, up 922% YoY (Page 6)
2 more points from Fermenta Biotech Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Fermenta Biotech Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Fermenta Biotech Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Fermenta Biotech Ltd said on order book & pipeline — free account, 30 seconds.
Fermenta Biotech Ltd — Quarterly revenue & net profit
Fermenta Biotech Ltd Q1 FY26 results — key figures
| ₹ Cr | Q1 FY26 | Q1 FY25 | YoY | Q4 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue | 136 | 78 | +74.4% | 140 | -2.6% |
| Operating profit (EBITDA) | 28 | 1 | +3430% | 37 | -23.6% |
| Operating margin | 20.73% | 1.02% | +19.7 pp | 26.42% | -5.7 pp |
| Profit before tax | 28 | -6 | — | 32 | -12.2% |
| Net profit (PAT) | 22 | -6 | — | 33 | -35.2% |
| EPS (₹) | 7.42 | -1.98 | — | 11.68 | -36.5% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹133 Cr, net profit ₹9 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Fermenta Biotech's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- RPG Life Sciences (Q1 FY26)
168.9 crores vs Rs. Key concall takeaways from RPG Life Sciences Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.
- SMS Pharmaceuticals (Q1 FY26)
Q1FY26 revenue from operations: ₹196.05 crore . Key concall takeaways from SMS Pharmaceuticals Ltd's Q1 FY26 earnings call — and how it ranks against sector…
- Morepen Laboratories (Q1 FY26)
Crores)**: . Key concall takeaways from Morepen Laboratories Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.
- NGL Fine Chem (Q1 FY26)
Q1FY26 Revenue from operations: ₹104.19 crores . Key concall takeaways from NGL Fine Chem Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Fermenta Biotech Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Fermenta Biotech Ltd Q1 FY26 results?
Q1FY26 Revenue from operations: INR 136 crore, up 79% YoY (Page 8) - Total Income Q1FY26: INR 145 crore, up 79% YoY (Page 8) - Nutrition business revenue Q1FY26: INR 114.6 crore, up 85% YoY (Page 7) - Human Nutrition volume growth: 83% YoY, 8% QoQ (Page 5) - Animal Nutrition volume growth: 45% YoY, down 17% QoQ (Page 5) - German subsidiary Q1FY26 revenue: INR 15.7 crore, up 588% YoY (Page 5) - EBITDA Q1FY26 INR 37 crore, up 922% YoY (Page 6) - Profit after tax Q1FY26 INR 21.6 crore vs loss last year (Page 6) - EBITDA for Q1FY26: INR 37 crore (up 922% YoY, down 9% QoQ) — Slide 6 - Operating EBITDA (without Real Estate): INR 35.3 crore (up 625% YoY, up 9% QoQ) — Slide 5 - Profit After Tax (PAT) for Q1FY26: INR 21.6 crore (vs INR 5.9 crore loss YoY, down 35% QoQ) — Slide 6
What is Fermenta Biotech Ltd share price analysis?
Fermenta Biotech Ltd currently shows a neutral. The stock trades at a P/E of 25.5 with a market cap of ₹1,395 Cr. Investors should review the full earnings analysis for detailed insights.
Keep Fermenta Biotech Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
